TEHRAN UNIVERSITY OF MEDICAL SCIENCES

Ocrelizumab Biosimilar Xacrel Demonstrates Equivalent Efficacy and Safety in Multiple Sclerosis Trial

7 months ago

• A Phase III clinical trial demonstrated that Xacrel, a biosimilar of ocrelizumab, is equivalent to Ocrevus in reducing the annualized relapse rate (ARR) in patients with relapsing-remitting multiple sclerosis (RRMS). • The study, conducted over 96 weeks, showed no significant difference in disability progression, relapse-free rates, or MRI lesion activity between patients treated with Xacrel and those treated with Ocrevus. • Safety profiles were comparable between the two groups, with similar incidences of adverse events, infusion reactions, and immunogenicity, supporting Xacrel as a potential cost-effective alternative to Ocrevus. • The findings suggest that Xacrel could expand access to B-cell-depleting therapy for MS patients, offering a more affordable treatment option without compromising efficacy or safety.

Topiramate and Pregabalin Reduce Migraine Frequency and Intensity in Pediatric Patients

7 months ago

• A network meta-analysis reveals that pregabalin and topiramate, with or without vitamin D3, significantly reduce migraine frequency in children and adolescents. • The study highlights that pregabalin resulted in a 63% reduction in migraine frequency, which increased to 88% when combined with vitamin D supplementation. • Flunarizine, levetiracetam, riboflavin, cinnarizine, and amitriptyline also showed potential in reducing migraine frequency, though further studies are needed for confirmation. • Amitriptyline, topiramate and valproate were associated with the greatest adverse events compared to placebo, underscoring the need for careful monitoring.